Furiex Pharmaceuticals Company Profile (NASDAQ:FURX)

About Furiex Pharmaceuticals (NASDAQ:FURX)

Furiex Pharmaceuticals logoFuriex Pharmaceuticals, Inc. is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Life Sciences Tools & Services
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:FURX
  • CUSIP: 36106P10
  • Web: N/A
  • Trailing P/E Ratio:
  • Foreward P/E Ratio: 99.78
  • P/E Growth:
  • Dividend Yield: 1.0%

Frequently Asked Questions for Furiex Pharmaceuticals (NASDAQ:FURX)

What is Furiex Pharmaceuticals' stock symbol?

Furiex Pharmaceuticals trades on the NASDAQ under the ticker symbol "FURX."

Who are some of Furiex Pharmaceuticals' key competitors?

How do I buy Furiex Pharmaceuticals stock?

Shares of Furiex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Furiex Pharmaceuticals' stock price today?

One share of Furiex Pharmaceuticals stock can currently be purchased for approximately $104.77.

MarketBeat Community Rating for Furiex Pharmaceuticals (NASDAQ FURX)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  85
MarketBeat's community ratings are surveys of what our community members think about Furiex Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Furiex Pharmaceuticals (NASDAQ:FURX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Furiex Pharmaceuticals (NASDAQ:FURX)
Price Target History for Furiex Pharmaceuticals (NASDAQ:FURX)
Analysts' Ratings History for Furiex Pharmaceuticals (NASDAQ:FURX)
No equities research coverage for this company has been tracked by MarketBeat.com


Earnings History for Furiex Pharmaceuticals (NASDAQ:FURX)
Earnings by Quarter for Furiex Pharmaceuticals (NASDAQ:FURX)
Earnings History by Quarter for Furiex Pharmaceuticals (NASDAQ FURX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2014Q114($0.63)($1.25)$10.01 million$6.40 millionViewN/AView Earnings Details
3/11/2014Q413($1.06)($0.63)$12.80 million$13.10 millionViewN/AView Earnings Details
8/6/2013Q2 2013($1.65)($2.32)$11.94 million$3.00 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.70$0.82$33.42 million$39.33 millionViewN/AView Earnings Details
3/6/2013Q4 2012($2.04)($0.90)$7.43 million$9.21 billionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Furiex Pharmaceuticals (NASDAQ:FURX)
Current Year EPS Consensus Estimate: $-2.27 EPS
Next Year EPS Consensus Estimate: $1.05 EPS


Dividend History for Furiex Pharmaceuticals (NASDAQ:FURX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Furiex Pharmaceuticals (NASDAQ:FURX)
Insider Trades by Quarter for Furiex Pharmaceuticals (NASDAQ:FURX)
Insider Trades by Quarter for Furiex Pharmaceuticals (NASDAQ:FURX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/24/2014Paul S CovingtonVPSell10,368$104.12$1,079,516.16View SEC Filing  
6/24/2014Sailash PatelCFOSell32,928$104.00$3,424,512.00View SEC Filing  
6/18/2014Paul S CovingtonVPSell45,691$104.11$4,756,890.01View SEC Filing  
6/17/2014Gail Frances McintyreSVPSell74,457$105.01$7,818,729.57View SEC Filing  
6/13/2014Paul S CovingtonVPSell3,228$104.25$336,519.00View SEC Filing  
6/10/2014Gail Frances McintyreSVPSell1,746$104.58$182,596.68View SEC Filing  
6/10/2014Paul S CovingtonVPSell2,872$104.63$300,497.36View SEC Filing  
6/10/2014Sailash PatelCFOSell1,504$104.68$157,438.72View SEC Filing  
9/10/2013Paul S CovingtonVPSell30,000$40.89$1,226,700.00View SEC Filing  
8/9/2013Peter CorrDirectorSell7,500$39.74$298,050.00View SEC Filing  
7/19/2013Gail Frances McintyreSVPSell10,581$40.00$423,240.00View SEC Filing  
3/12/2013Stephen W KaldorDirectorSell6,352$41.58$264,116.16View SEC Filing  
8/15/2012June Sherie AlmenoffPresidentBuy1,000$18.67$18,670.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Furiex Pharmaceuticals (NASDAQ:FURX)
Latest Headlines for Furiex Pharmaceuticals (NASDAQ:FURX)
No headlines for this company have been tracked by MarketBeat.com



Furiex Pharmaceuticals (FURX) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.